✦ LIBER ✦

Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma

✍ Scribed by N. Abildgaard; H. Glerup; J. Rungby; K. Bendix-Hansen; M. Kassem; K. Brixen; L. Heickendorff; J. L. Nielsen; E. F. Eriksen

Book ID: 114422883
Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 177 KB
Volume: 64
Category: Article
ISSN: 0902-4441
DOI: 10.1034/j.1600-0609.2000.90074.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biochemical markers of bone metabolism i

Biochemical markers of bone metabolism in multiple myeloma

✍ Evangelos Terpos 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 511 KB

Novel aspects of osteoclast activation a

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

✍ Ulrike Heider; Lorenz C. Hofbauer; Ivana Zavrski; Martin Kaiser; Christian Jakob 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Evaluation of bone disease in multiple m

Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients

✍ Michael G Alexandrakis; Freda H Passam; Niki Malliaraki; Constantinos Katachanak 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Long-term oral pamidronate treatment inh

Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma

✍ N. Abildgaard; J. Rungby; H. Glerup; K. Brixen; M. Kassem; H. Brincker; L. Heick 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Biochemical markers of bone turnover in

Biochemical markers of bone turnover in diagnosis of myeloma bone disease

✍ Omer Dizdar; Ibrahim Barista; Umut Kalyoncu; Omer Karadag; Gulsen Hascelik; Ayse 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

## Abstract This study was designed to explore the value of markers of bone turnover, macrophage inflammatory protein‐1α (MIP‐1α), and osteopontin (OPN) in the diagnosis of myeloma bone disease. Twenty‐five patients with newly diagnosed and untreated multiple myeloma (MM), and 22 age‐, sex‐, and bo

MULTIPLE MYELOMA: OPTIMAL USE OF SALMON

MULTIPLE MYELOMA: OPTIMAL USE OF SALMON CALCITONIN IN THE MANAGEMENT OF MYELOMA OSTEOCLASTIC BONE DISEASE

✍ Régis Bataille; Marc Tenoudji-Cohen; Jean-François Rossi 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB